Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Deciphering the molecular landscape of frontotemporal lobar degeneration: A network-based proteomic approach

Award Number: K23AG090757
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 09/10/2025
PERIOD OF PERFORMANCE END DATE: 05/31/2030

Group Awards By:

View Award Description

Deciphering the molecular landscape of frontotemporal lobar degeneration: A network-based proteomic approach - PROJECT SUMMARY/ABSTRACT This K23 career development award aims to support Dr. Rowan Saloner in acquiring the expertise to become a leading clinical researcher focused on unraveling the neurobiological underpinnings of clinical progression in frontotemporal lobar degeneration (FTLD), Alzheimer's disease (AD), and other related dementias (ADRD), Dr. Saloner is a clinical neuropsychology postdoctoral fellow transitioning to faculty at the University of California, San Francisco, Memory and Aging Center (MAC), This K23 will focus on large-scale proteomics, clinical characterization, and bioinformatics to identify fluid biomarker signatures of FTLD and their relationship to disease progression. Through the enriched multidisciplinary training environment at the MAC, Dr. Saloner aims to accomplish the following training goals: 1) clinical integration of deep molecular phenotyping of ADRD; 2) big data/bioinformatics; and 3) scientific leadership, Dr. Saloner will translate his K23 experience into future R01 efforts to integrate high-dimensional biological tools with detailed clinical phenotyping to refine personalized biomarkers for diagnosis, prognosis, and therapeutic target engagement in ADRD. Dr. Saloner has assembled an exemplary mentorship team with expertise in neurobehavioral aging (Primary Mentor Dr, Kaitlin Casaletto ), ADRD fluid biomarkers (Co-Primary Mentor Dr. Adam Boxer), proteomics (Co-Mentor Dr, Nicholas Seyfried), biostatistics (Co-Mentor Dr. John Karnak), disease progression modeling (Collaborator Dr. Adam Staffaroni), FTLD biology (Advisor Dr. Jennifer Yokoyama), and professional development (Advisor Dr. Joel Kramer). The central rationale is that the most potent therapeutics for ADRD will modify molecular targets that change early in disease and have downstream effects on neuron loss and cognitive decline. Cutting-edge proteomic platforms that measure thousands of proteins in a single biospecimen sample have advanced understanding of AD biology in living humans. However, far less is known regarding the molecular evolution of FTLD, a common cause of young-onset dementia for which there are no effective therapies. The proposed study will leverage large-scale proteomics in cerebrospinal fluid (CSF) and plasma to identify protein signatures that precede and predict brain atrophy and cognitive decline in carriers of autosomal dominant FTLD mutations, who represent an ideal population to study early ADRD biomarkers. Antemortem CSF and plasma proteomic data in sporadic, pathology-confirmed FTLD will also be leveraged to determine the degree to which genetically-derived protein signatures translate to sporadic FTLD, which represents the majority of FTLD cases. Examining deep molecular screening tools in relation to FTLD progression strongly aligns with Actions 1.B.1 ( Expand research to identify the molecular and cellular mechanisms underlying Alzheimer's disease and related dementias ) and 1.C, 1 ( Identify imaging and biomarkers to monitor disease progression ) of the 2022 National Plan to Address Alzheimer's Disease. Successful completion of study aims will advance discovery of early FTLD biology in humans and identify targets for the development of urgently needed FTLD biomarkers and treatments.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $199,830 )
2025	2025	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Aging Research	000	1	9/10/2025	NEW	$199,830
														Subtotal = $199,830

Grand Total All Awards = $199,830

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Deciphering the molecular landscape of frontotemporal lobar degeneration: A network-based proteomic approach

Award Number: K23AG090757

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 09/10/2025

PERIOD OF PERFORMANCE END DATE: 05/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer